Trustbridge Partners has acquired a majority stake in WeWork China, a SoftBank-backed company that was at one point valued at $5bn.
TriNetX had raised $102m in funding from investors including Merck & Co, Mitsui and Itochu before agreeing to a purchase by Carlyle.
Two weeks after filing to go public, Grail has instead accepted an $8bn acquisition offer from Illumina, which had spun off the cancer diagnostics technology developer five years ago.
Zhonggu Logistics has filed for a $218m on the Shanghai Stock Exchange, providing exits to Zhonggu Shipping and SoftBank.
The Washington State University neurological drug developer has gone public after issuing 12 million shares priced at $17 each.
Novartis-backed Inflazome, which advances University of Queensland and Trinity College Dublin research to develop treatments for inflammation, has been bought by Roche for $448m.
Inflazome, which advances University of Queensland and Trinity College Dublin research to develop treatments for inflammation, has been bought by Roche for $448m.
Compass Pathways has raised more than $127m in an upsized initial public offering that provided an exit to Otsuka Pharmaceuticals.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
